Syngenta will lease Novartis’ fermentation pilot plant and science laboratories in Basel, Switzerland
As a leading developer of next-generation biologicals products for agricultural use, Syngenta is expanding its biologicals research efforts and development capabilities significantly.
Syngenta has acquired Novartis’ repository of natural compounds and genetic strains for use in agriculture, while Novartis retains exclusive rights in the pharmaceutical repository. Novartis’ Natural Products and Biomolecular Chemistry team will also be transferred to Syngenta as part of the transaction.
Syngenta gains access to an important source of new agricultural leads due to this move, as well as integrated capabilities in bioengineering, data science, fermentation, downstream processing, and analytics.
Syngenta will also lease Novartis’ fermentation pilot plant and science laboratories in Basel, Switzerland, as part of the agreement, which is expected to close on June 1st this year. Since 2019, Syngenta and Novartis have collaborated successfully on research projects.
This acquisition follows Syngenta’s opening of a biologicals production facility in Orangeburg, South Carolina. The facility is Syngenta’s first world-scale production facility for agricultural biologicals in the US and will support growing demand for science-based and novel biological solutions in both the North and Latin American markets.
